Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 09/28 10:00:21 pm
63.3 USD   +1.17%
03:07p MERCK FOUNDATIO : Grant Expands YMCA’s Diabetes Prevention Pro..
09/28 Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Dire..
09/28 MSD ANIMAL HEAL : Demonstrates Commitment to Eliminate Rabies Worldw..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
03:07p MERCK FOUNDATION : Grant Expands YMCA’s Diabetes Prevention Program in Fiv..
09/28 Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
09/28 MSD ANIMAL HEALTH : Demonstrates Commitment to Eliminate Rabies Worldwide with D..
09/28 MERCK : Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy..
09/23DJMERCK : Keytruda Finds Fast Entry Into China Via Medical-Tourism Push
09/23 MERCK : to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October..
09/21 MERCK : Geneva Advisors Lowers stake in Merck & Co. (MRK)
09/20 MERCK : to Host Investor Teleconference to Discuss ESMO 2016 Highlights
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
09/20DJBusiness Watch -- WSJ
More news
Sector news : Pharmaceuticals - NEC
02:40pDJGLAXOSMITHKLINE : Appoints New Consumer Healthcare Chief
10:26aDJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:13a Yellen And Clinton Combo To Take Market Higher
09/28 Enrollment underway in Bayer and Merck's large-scale study of vericiguat in h..
09/27 Real Estate Leader CXW Gains Upside As Price Sags
09/26 Enrollment underway in Gemphire's mid-stage study of gemcabene in patients wi..
09/23 Industrial Sector Capped By Ships & Ports In September
Advertisement
Financials ($)
Sales 2016 39 719 M
EBIT 2016 13 608 M
Net income 2016 5 662 M
Debt 2016 5 481 M
Yield 2016 2,87%
P/E ratio 2016 30,73
P/E ratio 2017 20,81
EV / Sales 2016 4,54x
EV / Sales 2017 4,48x
Capitalization 175 038 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,1 $
Spread / Average Target 4,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.19.84%175 038
JOHNSON & JOHNSON16.23%326 636
ROCHE HOLDING LTD.-12.41%217 190
NOVARTIS AG-10.14%212 589
PFIZER INC.5.30%206 172
GLAXOSMITHKLINE PLC20.54%105 036
More Results